How validated receptor occupancy flow cytometry assays can impact decisions and support drug development

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 2, 2016, Pages 150-158

  Moulard, Maxime ^a   Ozoux, Marie Laure ^b  

^a BioCytex   (France)

^b SANOFI   (France)

Author keywords

AML; B cells; clinical trial; CLL; flow cytometry; immune monitoring; leukemia; oncology; quantification; standardization

Indexed keywords

AVE 9633; COLTUXIMAB RAVTANSINE; ISATUXIMAB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN;

BIOLOGICAL ACTIVITY; BLOOD; BONE MARROW; CANCER CELL; CASE STUDY; DRUG DEVELOPMENT; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; MEDICAL DECISION MAKING; MINIMUM ANTICIPATED BIOLOGICAL EFFECT LEVEL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; REVIEW; VALIDATION STUDY; B LYMPHOCYTE; BONE MARROW CELL; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, MYELOID; PLASMA CELL;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; DRUG DISCOVERY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS; LEUKEMIA, MYELOID; MYELOID CELLS; PLASMA CELLS;

EID: 84962119024     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21320     Document Type: Review

References (36)

1. Finkelstein JB., Federal task force seeks standards for immunotherapy biomarker studies. J Natl Cancer Inst 2009; 101: 704-706.
2. Freeman DJ, McDorman K, Ogbagabriel S, Kozlosky C, Yang BB, Doshi S, Perez-Ruxio JJ, Fanslow W, Starnes C, Radinsky T., Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer 2012; 11: 47.
3. Muñoz P, Mittelbrunn M, de la Fuente H, Pérez-Martínez M, García-Pérez A, Ariza-Veguillas A, Malavasi F, Zubiaur M, Sánchez-Madrid F, Sancho J., Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood 2008; 111: 3653-3664.
4. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V., SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent anti-tumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014; 20: 4574-4583.
5. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S., Phase1/2 study of lumilixumab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 115: 489-495.
6. Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E, Chindalore V, Bingham CO III, Davis JC., MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthristis: A phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamics biomarker assessments. Arthritis Res Ther 2011; 13: R177.
7. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CL, Rodan J, Murphy B, Roth B, McCaffery I, Gorsky KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I., Phase I, pharmacokinetic and pharmacodynamics study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor I. J Clin Oncol 2009; 27: 5800-5807.
8. Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, Stadtmauer EA., A phase I study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012; 159: 58-66.
9. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian S., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
10. Reilly M, Miller RM, Thomson MH, Patris V, Ryle P, McLoughlin L, Mutch P, Gilboy P, Miller C, Broekema M, Keogh B, McCormack W, Van de Wetering de Rooj J., Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody. Clin Pharmacol Therap 2013; 94: 593-600.
11. Martin DA, Churchill M, Flores-Suarez LP, Cardiel MH, Wallace D, Marin R, Phillips K, Laine JL, Dong H, Salinger D, Stevens E, Russel CB, Chung JB., A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013; 15: R164.
12. Stefabish EG, Danilenko DM, Wang H, O'Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fong F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M., A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011; 162: 1855-1870.
13. Lapusan S, Vidriales MB, Thomas X, De Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP., Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Investig N Drugs 2012; 30: 1121-1131.
14. Green CL, Brown L, Stewart JJ, Xu Y, Litwin V, McCloskey TW., Recommendations for the validation of flow cytometry testing during drug development: I instrumentation. J Immunol Methods 2011; 363: 104-119.
15. Cunliffe J, Derbyshire N, Keeler S, Coldwell R., An approach to the validation of flow cytometry methods. Pharma Res 2009; 26: 2551-2557.
16. Wu D, Patti-Diaz L, Hill CG., Development and validation of flow cytometry methods for pharmacodynamics clinical biomarkers. Bioanalysis 2010; 2: 1617-1626.
17. Boudousq V, Bobyk L, Busson M, Garambois V, Jarlier M, Charalambatou P, Pèlegrin A, Paillas S, Chouin N, Quenet F, Maquaire P, Torgue J, Navarro-Teulon I, Pouget JP., Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One 2013; 8: e69613.
18. Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius T., Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J Immunol 2012; 189: 5230-5239.
19. Pulczynski S, Boesen AM, Jensen OM., Antibody induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: An immunofluorescence and immunoelectron microscopy study. Blood 1993; 81: 1549-1557.
20. Goulet AC, Goldmacher VS, Lambert JM, Baron C, Roy DC, Kouassi E., Conjugation of Blocked Ricin to an Anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. Blood 1997; 90: 2364-2375.
21. Carter RH, Doody GM, Bolen JB, Fearon DT., Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. J Immunol 1997; 158: 3062-3069.
22. Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, Haioun C, Copie C, Varga A, Lambert J, Hatteville L, Ziti-Ljajic S, Caron A, Payrard S, Coiffier B., A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014; 20: 213-220.
23. Engelberts PJ, Badoil C, Beurskens FJ, Boulay-Moine D, Grivel K, Parren PW, Moulard M., A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: Proof of principle with rituximab and ofatumumab. J Immunol Methods 2013; 388: 8-17.
24. Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh VK, Ferrero E, Funaro A, Horenstein AL, Malavasi F., CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytom B Clin Cytom 2013; 84: 207-217.
25. Berthelier V, Tixier JM, Muller-Steffner H, Schuber F, Deterre P., Human CD38 is an authentic NAD(P)+ glycohydrolase. Biochem J 1998; 330: 1383-1390.
26. Lee HC, Munshi C, Graeff R., Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes. Mol Cell Biochem 1999; 193: 89-98.
27. EMEA. Guideline on Strategies to Identify and Mitigate Risks for First in Human Clinical Trials with Investigational Medicinal Products. London: EMEA; 2007.
28. Gibiansky L, Gibiansky E, Kakkar T, Ma P., Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008; 35: 573-591.
29. Ozoux ML, Guillemin H, Pascual MH, Cartot-Cotton S, Veyrat-Follet C, Valente D, Moulard M, Mauriac C, Deslandes A, Semiond D., A first-in-human phase I study of SAR650984, a humanized anti-CD38 antibody in patients with CD38+ hematological malignancies: Preliminary PK and PD results of escalation phase. AACR 2014, Abstract#2908.
30. Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA., CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 2007; 109: 1061-1068.
31. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S., Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood 2012; 119: 3705-3711.
32. Erickson HK, Park PU, Widdison Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA., Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006; 66: 4426-4433.
33. Lambert JM., Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005; 5: 543-549.
34. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R., Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010; 21: 84-92.
35. Cottin S, Ghani K, de Campos-Lima PO, Caruso M., Gemcitabine intercellular diffusion mediated by gap junctions: New implications for cancer therapy. Mol Cancer 2010; 9: 141.
36. Cowan AJ, Laszlo GS, Estey EH, Walter RB., Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) 2013; 18: 1311-1334.